This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Johnson & Johnson

Drug Names(s): TMC278, R-278474, rilpivirine

Description: TMC278 is a new non-nucleoside reversetranscriptase inhibitor that is highly active against most NNRTI-resistant clinical isolates.

Deal Structure: TMC278 is in development by Tibotec Pharmaceuticals, a unit of Johnson & Johnson.

Edurant News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug